Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia

Leukemia and Lymphoma

Volumn 47, Issue 8, 2006, Pages 1583-1592

  Rodriguez, Vilmarie ^a   Anderson, Peter M ^a   Litzow, Mark R ^a   Erlandson, Linda ^a   Trotz, Barbara A ^a   Arndt, Carola A S ^a   Khan, Shakila P ^a   Wiseman, Gregory A ^a  

^a MAYO CLINIC   (United States)

Author keywords

153Sm EDTMP; Acute myelogenous leukemia; Blood and marrow stem cell transplantation; Conditioning regimen; Gemtuzumab ozogamicin; Skeletal irradiation

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CALCIUM CARBONATE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; FUROSEMIDE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROCORTISONE; HYDROXYUREA; IDARUBICIN; LEXIDRONAM SAMARIUM SM 153; MELPHALAN; METHOTREXATE; MITOXANTRONE; PENTAMIDINE; PREDNISONE; THIOTEPA; THYMOCYTE ANTIBODY; TIOGUANINE; UNINDEXED DRUG; VANCOMYCIN;

ABSCESS; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTEREMIA; BLAST CELL; BONE MARROW BIOPSY; CANDIDIASIS; CASE REPORT; CYTOGENETICS; ENTERITIS; FEMALE; FEVER; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; HYDRATION; HYPERBILIRUBINEMIA; HYPOCALCEMIA; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; NAUSEA; PERIPHERAL NEUROPATHY; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; STAPHYLOCOCCUS INFECTION; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TRISOMY 8; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; BONE MARROW; DOSE-RESPONSE RELATIONSHIP, RADIATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, ACUTE; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; QUALITY OF LIFE; RADIOISOTOPES; REMISSION INDUCTION; SAMARIUM; TRANSPLANTATION CONDITIONING;

EID: 33748563604     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600580817     Document Type: Article

References (53)

1. Mehta, J and Powles, R and Singhal, S and Horton, C and Tait, D and Milan, S and (1995) Autologous bone marrow transplantation for acute myeloid leukemia in first remission: Identification of modifiable prognostic factors Bone Marrow Transplant, 16, pp. 499-506.
2. Parisi, E and Draznin, J and Stoopler, E and Schuster, S and Porter, D and Sollecito, T. (2002) Acute myelogenous leukemia: Advances and limitations of treatment Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 93, pp. 257-263.
3. Woods, W and Neudorf, S and Gold, S and Sanders, J and Buckley, J and Barnard, D and Children's Cancer Group. (2001) A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission Blood, 97, pp. 56-62.
4. Pedersen-Bjergaard, J and Rowley, J. (1994) The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation Blood, 83, pp. 2780-2786.
5. Brozek, I and Babinska, M and Kardas, I and Wozniak, A and Balcerska, A and Hellmann, A and (2003) Cytogenetic analysis and clinical significance of chromosome 7 aberrations in acute leukaemia J Appl Genet, 44, pp. 401-412.
6. Smith, S and Le Beau, M and Huo, D and Karrison, T and Sobecks, R and Anastasi, J and (2003) Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series Blood, 102, pp. 43-52.
7. Pui, C and Relling, M and Rivera, G and Hancock, M and Raimondi, S and Heslop, H and (1995) Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases Leukemia, 9, pp. 1990-1996.
8. Yakoub-Agha, I and de La Salmoniere, P and Ribaud, P and Sutton, L and Wattel, E and Kuentz, M and (2000) Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: A long-term study of 70 patients-report of the French society of bone marrow transplantation J Clin Oncol, 18, pp. 963-971.
9. Helenglass, G and Powles, R and McElwain, T and Lakhani, A and Milan, S and Gore, M and (1988) Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission Bone Marrow Transplant, 3, pp. 21-29.
10. Anderson, J and Appelbaum, F and Schoch, G and Gooley, T and Anasetti, C and Bensinger, W and (1996) Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: A phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors J Clin Oncol, 14, pp. 220-226.
11. Dusenbery, K and Steinbuch, M and McGlave, P and Ramsay, N and Blazar, B and Neglia, J and (1996) Autologous bone marrow transplantation in acute myeloid leukemia: The University of Minnesota experience Int J Radiat Oncol Biol Phys, 36, pp. 335-343.
12. Mehta, J and Powles, R and Singhal, S and Horton, C and Tait, D and Treleaven, J. (1996) Melphalan-total body irradiation and autologous bone marrow transplantation for adult acute leukemia beyond first remission Bone Marrow Transplant, 18, pp. 119-123.
13. Ringden, O and Labopin, M and Tura, S and Arcese, W and Iriondo, A and Zittoun, R and Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). (1996) A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia Br J Haematol, 93, pp. 637-645.
14. Michallet, M and Thomas, X and Vernant, J and Kuentz, M and Socie, G and Esperou-Bourdeau, H and (2000) Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: A retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM) Bone Marrow Transplant, 26, pp. 1157-1163.
15. Clift, R and Buckner, C and Appelbaum, F and Bearman, S and Petersen, F and Fisher, L and (1990) Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens Blood, 76, pp. 1867-1871.
16. Olivieri, A and Capelli, D and Montanari, M and Brunori, M and Massidda, D and Poloni, A and (2001) Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: A single center experience Bone Marrow Transplant, 27, pp. 1189-1195.
17. Gorin, N and Labopin, M and Fouillard, L and Meloni, G and Frassoni, F and Iriondo, A and (1996) Retrospective evaluation of autologous bone marrow transplantation versus allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia: A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT) Bone Marrow Transplant, 18, pp. 111-117.
18. Novitzky, N and Thomas, V and Stubbings, H. (2003) Intensified myeloablative therapy and autologous stem-cell transplantation for patients with AML: Single center experience Cytotherapy, 5, pp. 139-146.
19. Bartlett, M and Webb, M and Durrant, S and Morton, A and Allison, R and Macfarlane, D. (2002) Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies Eur J Nucl Med Mol Imaging, 29, pp. 1470-1477.
20. Turner, J and Claringbold, P and Berger, J and Martindale, A and Glancy, J. (1992) 153Sm-EDTMP and melphalan chemoradiotherapy regimen for bone marrow ablation prior to marrow transplantation: An experimental model in the rat Nucl Med Commun, 13, pp. 321-329.
21. Goeckeler, W and Troutner, D and Volkert, W and Edwards, B and Simon, J and Wilson, D. (1986) 153Sm radiotherapeutic bone agents Int J Rad Appl Instrum B, 13, pp. 479-482.
22. Turner, J and Martindale, A and Sorby, P and Hetherington, E and Fleay, R and Hoffman, R and (1989) Samarium-153 EDTMP therapy of disseminated skeletal metastasis Eur J Nucl Med, 15, pp. 784-795.
23. Bayouth, J and Macey, D and Kasi, L and Fossella, F. (1994) Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases J Nucl Med, 35, pp. 63-69.
24. Serafini, A. (2000) Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases Cancer, 88 (Suppl), pp. 2934-2939.
25. Franzius, C and Bielack, S and Sciuk, J and Vollet, B and Jurgens, H and Schober, O. (1999) High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma Nuklearmedizin, 38, pp. 337-340.
26. Franzius, C and Bielack, S and Flege, S and Eckardt, J and Sciuk, J and Jurgens, H and (2001) High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma Nuklearmedizin, 40, pp. 215-220.
27. Franzius, C and Schuck, A and Bielack, S. (2002) High-dose samarium-153 ethylene diamine tetramethylene phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases J Clin Oncol, 20, pp. 1953-1954.
28. Anderson, P and Wiseman, G and Dispenzieri, A and Arndt, C and Hartmann, L and Smithson, W and (2002) High-dose samarium-153 ethylene diamine tetramethylene phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases J Clin Oncol, 20, pp. 189-196.
29. Hogan, W and Lacy, M and Wiseman, G and Fealey, R and Dispenzieri, A and Gertz, M. (2001) Successful treatment of POEMS syndrome with autologous hematopoietic progenitor cell transplantation Bone Marrow Transplant, 28, pp. 305-309.
30. Macfarlane, D and Durrant, S and Bartlett, M and Allison, R and Morton, A. (2002) 153Sm EDTMP for bone marrow ablation prior to stem cell transplantation for haematological malignancies Nucl Med Commun, 23, pp. 1099-1106.
31. Peylan-Ramu, N and Shapira, M and Amir, G and Klein, M and Chisin, R and Slavin, S and (2003) High dose 153-samarium-EDTMP followed by non-myeloablative allogeneic stem cell transplantation in resistant hematological malignancies [abstract] Prog Proc Am Soc Clin Oncol, 22, pp. 839.
32. Wiseman, G and Dispenzieri, A and Anderson, P. (2001) Phase I high dose 153Samarium ethylenediaminetetramethylenephosphonoate (153-Sm EDTMP) and melphalan therapy of multiple myeloma (MM) with peripheral blood stem cell (PBSC) support [abstract] J Nucl Med, 42, pp. 155P.
33. Dispenzieri, A and Wiseman, G and Lacy, M and Litzow, M and Anderson, P and Gastineau, D and (2005) A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma Leukemia, 19, pp. 118-125.
34. Rodriguez, V and Erlandson, L and Arndt, C and Wiseman, G and Anderson, P. (2005) Low toxicity and efficacy of (153)samarium-EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia Pediatr Transplant, 9, pp. 122-126.
35. Inverardi, L and Linetsky, E and Pileggi, A and Molano, R and Serafini, A and Paganelli, G and (2004) Targeted bone marrow radioablation with 153Samarium-lexidronam promotes allogeneic hematopoietic chimerism and donor-specific immunologic hyporesponsiveness Transplantation, 77, pp. 647-655.
36. Bernstein, I. (2000) Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate Leukemia, 14, pp. 474-475.
37. Gopal, A and Rajendran, J and Petersdorf, S and Maloney, D and Eary, J and Wood, B and (2002) High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma Blood, 99, pp. 3158-3162.
38. Gopal, A and Gooley, T and Maloney, D and Petersdorf, S and Eary, J and Rajendran, J and (2003) High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: A multivariable cohort analysis Blood, 102, pp. 2351-2357.
39. Jurcic, J. (2000) Antibody therapy of acute myelogenous leukemia Cancer Biother Radiopharm, 15, pp. 319-326.
40. Matthews, D and Appelbaum, F and Eary, J and Fisher, D and Durack, L and Bush, S and (1995) Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation Blood, 85, pp. 1122-1131.
41. Matthews, D and Appelbaum, F and Press, O and Eary, J and Bernstein, I. (1997) The use of radiolabeled antibodies in bone marrow transplantation for hematologic malignancies Cancer Treat Res, 77, pp. 121-139.
42. Matthews, D and Appelbaum, F and Eary, J and Fisher, D and Durack, L and Hui, T and (1999) Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome Blood, 94, pp. 1237-1247.
43. Copelan, E and Penza, S and Elder, P and Belt, P and Scholl, M and Hehmeyer, D and (1996) Influence of graft-versus-host disease on outcome following allogeneic transplantation with radiation-free preparative therapy in patients with advanced leukemia Bone Marrow Transplant, 18, pp. 907-911.
44. Horowitz, M and Gale, R and Sondel, P and Goldman, J and Kersey, J and Kolb, H and (1990) Graft-vs.-leukemia reactions after bone marrow transplantation Blood, 75, pp. 555-562.
45. Appelbaum, F and Sandmaier, B and Brown, P and Kaplan, D and Ketring, A and Goeckeler, W and (1988) Myelosuppression and mechanism of recovery following administration of 153Samarium-EDTMP Antibody Immunoconjugates Radiopharm, 1, pp. 263-270.
46. Bonetti, F and Montagna, D and Porta, F and Lanfranchi, A and Zecca, M and Comoli, P and (1995) Autologous bone marrow transplantation for acute myeloid leukaemia in children using total body irradiation and melphalan as conditioning regimen Leukemia, 9, pp. 570-575.
47. Maraninchi, D and Pico, J and Hartmann, O and Gastaut, J and Kamioner, D and Hayat, M and (1986) High-dose melphalan with or without marrow transplantation: A study of dose-effect in patients with refractory and/ or relapsed acute leukemias Cancer Treat Rep, 70, pp. 445-448.
48. Cesaro, S and Meloni, G and Messina, C and Pillon, M and Proglia, A and Lanino, E and Italian Pediatric Group for Bone Marrow Transplantation. (2001) High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: Results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation Bone Marrow Transplant, 28, pp. 131-136.
49. Giralt, S and Thall, P and Khouri, I and Wang, X and Braunschweig, I and Ippolitti, C and (2001) Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation Blood, 97, pp. 631-637.
50. Lynch, M and Petersen, F and Appelbaum, F and Bensinger, W and Clift, R and Storb, R and (1995) Phase II study of busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies Bone Marrow Transplant, 15, pp. 59-64.
51. Della Volpe, A and Ferreri, A and Annaloro, C and Mangili, P and Rosso, A and Calandrino, R and (2002) Lethal pulmonary complications significantly correlate with individually assessed mean lung dose in patients with hematologic malignancies treated with total body irradiation Int J Radiat Oncol Biol Phys, 52, pp. 483-488.
52. Giralt, S and Bensinger, W and Goodman, M and Podoloff, D and Eary, J and Wendt, R and (2003) 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: Results of two phase 1/2 trials Blood, 102, pp. 2684-2691.
53. Anderson, P and Ramsay, N and Shu, X and Rydholm, N and Rogosheske, J and Nicklow, R and (1998) Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation Bone Marrow Transplant, 22, pp. 339-344.